F075 Vascular Anomalies: Classification, Clinical Challenges, and Management Update
DESCRIPTION
Dermatologists play a primary role in diagnosing and directing the management of vascular anomalies. Over the last decade there have been significant developments in the understanding of the pathogenesis of vascular anomalies which have impacted clinical practice. In this session, experts in the field will discuss key topics and literature relating to the evaluation and management of vascular anomalies. Included topics will cover important advances in the literature, laser management of vascular anomalies, management of complicated infantile hemangiomas and PHACE syndrome and evolving targeted therapies for vascular anomalies.
LEARNING OBJECTIVES
Consider and examine recent key publications from the vascular anomalies literature
Develop tools for laser therapy for infantile hemangiomas, port wine birthmarks and other vascular malformations
Describe new and emerging targeted therapies for patients with complex vascular anomalies and related syndromes
SCHEDULE
3:30 PM
Literature Every Vascular Anomalies Expert Should Know
Maria Cecilia Garzon, MD, FAAD
3:50 PM
Vascular Anomalies in the Era of Targeted Therapies
Beth Ann Drolet, MD, FAAD
4:10 PM
PHACE syndrome: Updates and Controversies
Dawn H. Siegel, MD, FAAD
4:30 PM
Hemangiomas in Pre-Term Infants: Isights from the GESTA study
Ilona J. Frieden, MD, FAAD
4:50 PM
Laser Management of Vascular Anomalies
Erin F. Mathes, MD, FAAD
DIRECTOR
Sheilagh M. Maguiness, MD, FAAD
University of Minnesota
SPEAKERS
Beth Ann Drolet, MD, FAAD
Ilona J. Frieden, MD, FAAD
UCSF
Maria Cecilia Garzon, MD, FAAD
Erin F. Mathes, MD, FAAD
Dawn H. Siegel, MD, FAAD
DISCLOSURES
Beth Ann Drolet, MD, FAAD
Arkayli Biosciences – Founder(Stock);
Ilona J. Frieden, MD, FAAD
Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Palvella Therapeutics – Consultant (1099 relationship)(Honoraria); Pierre Fabre Dermatologie – Consultant (1099 relationship)(Honoraria);
Maria Cecilia Garzon, MD, FAAD
No financial relationships exist with ineligible companies.
Sheilagh M. Maguiness, MD, FAAD
DYPER – Other(Fees); Galderma – Advisory Board(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Stryke Club LLC – Founder(No Compensation Received);
Erin F. Mathes, MD, FAAD
Novartis – Consultant (1099 relationship)(Fees);
Dawn H. Siegel, MD, FAAD
No financial relationships exist with ineligible companies.